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Abstract
Background: Fumaric acid esters (FAEs), an oral immunomodulating treatment for psoriasis and multiple sclerosis, have been
anecdotally associated with proximal renal tubular dysfunction due to a drug-induced Fanconi syndrome. Few data are
available on clinical outcomes of FAE-induced Fanconi syndrome.
Methods: Descriptive case series with two cases of Fanconi syndrome associated with FAE treatment diagnosed at two Dutch
university nephrology departments, three cases reported at the Dutch and German national pharmacovigilance databases and
six previously reported cases.
Results: All 11 cases involved female patients with psoriasis. The median age at the time of onset was 38 years [interquartile
range (IQR) 37–46]. Patients received long-term FAEs treatment with a median treatment duration of 60 months (IQR 28–111).
Laboratory tests were typically signiﬁcant for low serum levels of phosphate and uric acid, while urinalysis showed glycosuria
and proteinuria. Eight (73%) patients had developed a hypophosphataemic osteomalacia and three (27%) had pathological bone
fractures. All patients discontinued FAEs, while four (36%) patients were treated with supplementation of phosphate and/or
vitamin D. Five (45%) patients had persisting symptoms despite FAEs discontinuation.
Conclusions: FAEs treatment can cause drug-induced Fanconi syndrome, but the association has been reported infrequently.
Female patientswith psoriasis treated long termwith FAEs seem to be particularly at risk. Physicians treating patientswith FAEs
should be vigilant and monitor for the potential occurrence of Fanconi syndrome. Measurement of the urinary albumin:total
protein ratio is a suggested screening tool for tubular proteinuria in Fanconi syndrome.
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Introduction
Fumaric acid esters (FAEs) are smallmoleculeswith immunomodu-
lating effects that have been used as an oral treatment for psoriasis
for four decades [1]. Since 1994, FAEs are an approved treatment for
psoriasis in Germany. The licensed FAE formulation Fumaderm®
(Biogen Idec, Ismaning, Germany) is amixture of dimethylfumarate
andmonoethylfumarate salts [2]. Currently, Fumadermisoneof the
most commonly usedﬁrst-line systemic treatments inGermany [3].
In other countries, FAEs are increasingly used as an unlicensed
treatment for psoriasis. The European S3 guidelines recommend
FAEs as a treatment for moderate-to-severe psoriasis on the
basis of their positive efﬁcacy and safety proﬁle [4]. The U.S.
Food and Drug Administration and the European Medicines
Agency approved an FAE formulation containing dimethylfuma-
rate (Tecﬁdera®; Biogen Idec, Cambridge,MA, USA) as a treatment
for multiple sclerosis in 2013 and 2014, respectively [5].
FAEs have been anecdotally linked to renal adverse events,
such as acute kidney injury and Fanconi syndrome (FS) [6–9]. FS
is deﬁned by a generalized dysfunction of the proximal renal tu-
bules, which can lead to an impaired resorption of glucose,
amino acids and phosphate. A complication of FS is osteomal-
acia, which can lead to bone fractures and bone pain [10]. Several
drugs can induce FS, such as tenofovir, ifosfamide, aminoglyco-
side antibiotics and FAEs (see Table 1) [7, 10]. There have been
only a limited number of cases described of FS associated with
FAEs. Consequently, few data are available on the clinical presen-
tation and treatment of FAE-induced FS.
Here, we assessed clinical and treatment outcomes of drug-
induced FS associated with FAEs treatment.
Materials and methods
This is a descriptive case series of FAE-associated FS in patients
with psoriasis. We described two new cases that were diagnosed
at our department.We reviewed clinical features, laboratory ﬁnd-
ings and treatment outcomes. Measurements of serum levels of
substances such as phosphate, calcium and 1,25-dihydroxyvita-
min D were performed according to standard operating pro-
cedures at the Department of Clinical Chemistry. Additional
testing to exclude the differential diagnoses of FS involved genet-
ic testing or radiologic evaluation.
We searched for additional cases in pharmacovigilance data-
bases of the Netherlands Pharmacovigilance Centre Lareb and
theGerman Federal Institute for Drugs andMedical Devices [Bun-
desinstitut für Arzneimittel und Medizinprodukte (BfArM)] up to
August 2015. We chose these two national pharmacovigilance
databases given that FAEs are extensively used in these countries
[3, 11]. In addition, Medline and Embase databases were searched
up to August 2015 for published cases.
We used descriptive statistical methods to analyse data.
Results
Case characteristics
We included a total of 11 patients who developed FS during treat-
mentwith FAEs. Two caseswere diagnosed at the nephrology de-
partment of two Dutch university medical centres, three cases
were identiﬁed in German and Dutch pharmacovigilance data-
bases and six case reportswere found through a literature search.
The clinical characteristics of the cases are presented in Table 2.
All cases involved female patients with psoriasis. The median
age at the time of onset of FS was 38 years [interquartile range
(IQR) 37–46]. The median treatment duration with FAEs was 60
months (IQR 28–111) and the median daily FAEs dosage was
840 mg (IQR 720–1290). Data on body mass were available for four
patients [median 20.9 kg/m2 (IQR 20.3–23.6)].
In most cases, patients did not exhibit any symptoms. The
most frequently reported presenting symptoms of FSwere gener-
alized weakness (27%), myalgia (27%) and arthralgia (27%) (see
Table 3). Laboratory tests often displayed low serum levels of
phosphate (73%), high alkaline phosphatase (45%) and low uric
acid (45%). Urinalysis typically showed glycosuria (73%), protein-
uria (64%), aminoaciduria (27%) and phosphaturia (27%). Diagno-
sis of FS was based on laboratory test results. Five (45%) patients
were diagnosed with a hypophosphataemic osteomalacia, of
whom three (27%) patients suffered from multiple pathological
bone fractures. FAEs treatment was discontinued in almost all
cases; two reports did not describewhether FAEs were discontin-
ued. Four (36%) patients were treated with supplementation of
phosphate and three (27%) with vitamin D supplementation.
Complete improvement was reported in four (36%) patients, par-
tial improvement in one (9%) patient and therewere ﬁve (45%) pa-
tients who had no improvement. In one (9%) case, the symptoms
of FS recurred twice upon rechallenges with FAEs [12].
Below, we describe detailed information on clinical features
and outcomes of the novel FS cases.
New cases of FAE-associated FS
A 37-year-old female patient with plaque psoriasis developed FS
during FAE treatment (patient no. 7; see Tables 2 and 4). This
Table 1. Overview of drugs that can cause drug-induced FS [7, 10]
Drug Class of drug Indications
Adefovir Antiviral Hepatitis B
Aminoglycosides, e.g.
gentamicin,
tobramycin,
amikacin
Antibiotic Bacterial infections
Aspirin Cyclooxygenase
inhibitor
Pain, fever
Azacitidine Cytostatic Types of cancer
Carboplatin Cytostatic Types of cancer
Cidofovir Antiviral Cytomegalovirus
retinitis
Cisplatin Cytostatic Types of cancer
Deferasirox Iron chelator Chronic iron
overload
Didanosine Antiviral HIV
FAEs, e.g. dimethyl
fumarate
Immunomodulator Psoriasis, multiple
sclerosis
Ifosfamide Cytostatic Types of cancer
Imatinib mesylate Tyrosine kinase
inhibitor
Leukaemia
Mercaptopurine Cytostatic Leukaemia
Ranitidine Histamine
antagonist
Gastroesophageal
reﬂux, peptic ulcer
disease
Streptozocin Cytostatic Types of cancer
Suramin Antiparasitic Trypanosomiasis,
onchocerciasis
Tenofovir Antiviral HIV, hepatitis B
Tetracyclines, e.g.
tetracycline
Antibiotic Bacterial infections,
acne
Valproic acid Anticonvulsant Epilepsy, bipolar
disorder, migraine
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Table 2. Overview of reported cases of drug-induced FS associated with FAEs treatment in patients with psoriasis
Patient
no.
Reference
(year) Sex
Age
(years)
Body
weight,
height,
BMI
FAE
treatment
duration
(months) FAE dosage per day Complaints Laboratory deviations Osteomalacia Therapy Outcome
1 Fliegner and
Spiegel
[12] (1992)
F 46 NR 16 1736 mga (960 mg
DMF + 776 mg MEF)
Arthralgia,
myalgia,
difﬁculties with
walking,
immobility
Serum: low phosphate, low
uric acid, increased
alkaline phosphatase
Urine: glycosuria,
proteinuria
Yes FAE discontinuation.
Oral phosphate and
vitamin D3
supplementation
Complete
improvement.
Recurrence after
re-treatment
with FAEs
2 Haviv et al.
[13] (1999)
F 48 47 kg,
152 cm,
20.3
12 NR Generalized
weakness,
dyspnoea
Serum: increased alkaline
phosphatase, low
phosphate, increased
PTH, vitamin B12
deﬁciency, low total
calcium
Urine: glycosuria,
aminoaciduria,
phosphaturia, uric
aciduria
Yes FAE discontinuation.
Oral phosphate
supplementation
Improvement of
the respiratory
capacity
3 Raschka
and Koch
[6] (1999)
F 38 57 kg,
168 cm,
20.2
60 840 mga Fatigue, weakness,
polydipsia
Serum: low uric acid, low
phosphate
Urine: proteinuria,
glycosuria
No FAE discontinuation.
Oral phosphate
supplementation
No improvement
within 6 months
4 Schilling
and
Schopf
[14] (1999)
F 35 NR ∼36 Max. 1290 mgb
(720 DMF + 570
MEF)
Pain in feet,
myalgia
Serum: increased alkaline
phosphatase, low
phosphate, low uric acid
Urine: glycosuria,
proteinuria,
hypercalciuria
Yes FAEs discontinuation Complete
improvement
within 8 months
5 Warzecha
et al. [15]
(2001)
F 48 NR ∼120 NR Multiple
pathological
bone fractures,
myalgia
Serum: increased alkaline
phosphatase, low
phosphate, low vitamin
D3
Urine: proteinuria,
aminoaciduria,
glycosuria
Yes FAEs discontinuation.
Oral vitamin D3
supplementation
Complete
improvement
within 3 months
6 Reid et al.
[16] (2013)
F 37 NR 25 720 mg Generalized
weakness and
pain in her feet,
multiple
pathologic bone
fractures
Serum: increased serum
alkaline phosphatase,
low phosphate, low uric
acid, low potassium
Urine: proteinuria,
glycosuria,
aminoaciduria,
hypercalciuria
Yes FAEs discontinuation Complete
improvement
within 4 weeks
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Table 2. Continued
Patient
no.
Reference
(year) Sex
Age
(years)
Body
weight,
height,
BMI
FAE
treatment
duration
(months) FAE dosage per day Complaints Laboratory deviations Osteomalacia Therapy Outcome
7 This report F 37 65 kg,
174 cm,
21.5
180 120–480 mg DMFb None Serum: low phosphate, low
uric acid, low PTH
Urine: Proteinuria,
glycosuria,
hypercalciuria,
phosphaturia
No FAEs discontinuation No improvement
8 This report F 40 NR 84 720 mg DMF None Serum: low phosphate, low
calcium, increased PTH,
low bicarbonate, low
vitamin B12
Urine: proteinuria,
glycosuria,
phosphaturia
No FAEs discontinuation Partial
improvement
9 This report
(Lareb)
F 31 83 kg,
167 cm,
29.8
60 NR Spontaneous bone
fracture
NR Yes FAEs discontinuation.
Phosphate and
vitamin D
supplementation
No improvement
10 This report
(BfArM)
F 45–49 NR 120 NR NR NR Yes NR No improvement
11 This report
(BfArM)
F 29–35 NR NR NR NR NR Yes NR NR
DMF, dimethylfumate; F, female; FAEs, fumaric acid esters; M, male; MEF, monoethylfumarate; NR, not reported; BMI, body mass index.
aUnlicensed FAE formulation containing dimethylfumarate plus monoethylfumarate salts.
bLicensed German FAE formulation containing dimethylfumarate plus monoethylfumarate salts (Fumaderm).
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patient had a history of psoriasis from the age of 20 years and
had been previously treated with phototherapy and topical treat-
ments. She had been treated with oral FAEs for 15 years and had
only temporarily stopped FAEs during pregnancy. Her medical
history was remarkable for two miscarriages, migraine and re-
current urinary tract infections. She used FAEs (Fumaderm)
215 mg dimethylfumarate once per day, rizatriptan 5 mg as
needed, an ethinylestradiol/gestodene contraceptive and calci-
potriol/betamethasone dipropionate ointment as needed. She
had no history of drug use known to cause drug-induced FS.
The psoriasis was well controlled with FAEs and there were no
adverse events. Routine urinalyses throughout FAE treatment
indicated persisting proteinuria and glycosuria, therefore she
was referred to the nephrology department for further analysis.
Additional laboratory testing showed a hypophosphataemia
(serum phosphate 0.86 mmol/L, RR 0.90–1.50) with a normal
serum creatinine level (74 μmol/L, RR 49–90) and a normal esti-
mated glomerular ﬁltration rate (eGFR) >60 mL/min/1.73 m2 (see
Table 3). The fractional phosphate excretion was 22%, suggest-
ing renal phosphate wasting. There was also a low serum level
of uric acid of 0.09 mmol/L (RR 0.14–0.34); the fractional uric
acid excretion was >73%. Further urinalysis revealed a tubular
proteinuria (0.86 g protein/24 h). There was also glycosuria
(1+ glucose on dipstick) in the face of a normal glycated haemo-
globin level of 32 mmol/mol Hb (RR 20–42). She also had hyper-
calciuria and nephrolithiasis. Her serum calcium level was
normal. The parathyroid hormone (PTH) level was decreased
(0.7 pmol/L, RR 1.4–7.3) and PTH-like peptide was not present.
Differential diagnoses as Dent’s disease and sarcoidosis were
excluded by genetic mutation testing and by chest radiograph
evaluation, respectively. The ﬁndings in this case were consist-
ent with a drug-induced FS. However, although unlikely, a new
genetic entity cannot be excluded. FAE treatment was subse-
quently discontinued. However, the laboratory and urine abnor-
malities persisted.
A second case of FAE-associated FS involved a 40-year-old
female patient who had plaque psoriasis since the age of
8 years (patient no. 8; see Tables 2 and 4). Her medical history
was remarkable for hypercholesterolaemia and recurrent
vaginal yeast infections, and she was recently diagnosed with
a vitamin B12 deﬁciency. Her medication use included atorvas-
tatin 10 mg once daily, ﬂuconazole 150 mg as needed and vita-
min B12 injections. There was no prior use of drugs linked to
drug-induced FS. She had previously been treated with topical
psoriasis treatments and phototherapy. In May 2008, she
started FAE treatment 215 mg three to six times per day. Her
psoriasis was well controlled and she reported no adverse
events. She had used FAEs continuously for 7 years. Routine
urinalysis showed persisting proteinuria, and therefore she
was referred to the nephrology department. Additional testing
was signiﬁcant for hypophosphataemia (serum phosphate
0.58 mmol/L, RR 0.80–1.40), hypocalcaemia (serum calcium
2.16 mmol/L, RR 2.20–2.65), an increased PTH level of 9.1 pmol/L
(RR 1.4–7.3) and a slightly decreased serum bicarbonate level
of 19.9 mmol/L (RR 21.0–27.0) (see Table 3). The fractional
phosphate excretion was 30.6%, which is in line with renal
phosphate wasting. The serum creatinine level was within
the normal range (87 μmol/L, RR 55–90), as was the eGFR of
63 mL/min/1.73 m2 (RR >60). Urinalysis was signiﬁcant for
glycosuria (3+ glucose on dipstick) and tubular proteinuria
(0.38 g protein/L). Based on these ﬁndings, a diagnosis of
Table 3. Overview of characteristics of drug-induced FS observed in
cases associated with FAE treatment for psoriasis (n = 11)
Characteristics Frequency in cases linked to FAEs
Subjective symptoms
Myalgia 3
Generalized weakness 3
Arthralgia/pain in feet 3
Fatigue 1
Polydipsia 1
Immobility 1
Dyspnoea 1
Laboratory abnormalities
Low phosphate 8
High alkaline phosphatase 5
Low uric acid 5
High PTH 2
Low vitamin B12 2
Low calcium 2
Low potassium 1
Low vitamin D3 1
Low bicarbonate 1
Low PTH 1
Urine analysis abnormalities
Glycosuria 8
Proteinuria 7
Aminoaciduria 3
Hypercalciuria 3
Phosphaturia 3
Uric aciduria 1
Complications
Osteomalacia 8
Pathological bone fractures 3
Table 4. Laboratory data characteristics from the two new cases
of drug-induced FS associated with FAE treatment
Characteristics (reference values)
Patient
no. 7
Patient
no. 8
Serum
eGFR (>60 mL/min/1.73 m2) >60 63
Creatinine (49–90 μmol/L) 74 87
Uric acid (0.14–0.34 mmol/L) 0.09 NA
Phosphate (0.90–1.50 mmol/L) 0.86 0.58
1,25-Dihydroxyvitamin D3
(38–183 pmol/L)
259 69
25-Hydroxyvitamin D3 (50–250 nmol/L) 161 71
PTH (1.4–7.3 pmol/L) 0.7 9.1
PTH-like peptide Negative NA
Alkaline phosphatase (0–97 U/L) 43 NA
Calcium (2.20–2.65 mmol/L) 2.50 2.16
Bicarbonate (21.0–27.0 mmol/L) 26 19.9
HbA1c (26–42 mmol/mol) 32 NA
Glucose (4–6.1 mmol/L) NA 4.8
Urine
Proteinuria (dipstick) Positive (2+) Positive (1+)
Proteinuria (g protein/24 h) 0.86 0.38
Glycosuria Positive (1+) Positive (3+)
Hypercalciuria (mmol/L) 4.5 NA
Creatinine (mmol/L) 5.1 4.7
Phosphate (mmol/L) 16 9.6
Fractional phosphate excretion 22% 31%
Fractional uric acid excretion >73% NA
eGFR, estimated glomerular ﬁltration rate; NA, not available.
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FAE-induced FS was made. It is likely that the patient’s vitamin
B12 deﬁciency is part of FS, considering that vitamin B12 is
taken up at the proximal renal tubule [17]. Pernicious anaemia
as an alternative reason for the vitamin B12 deﬁciency was
excluded, as antibodies to intrinsic factor were not present.
Vitamin D is also taken up in the proximal tubule [17], but in
this case serum 1,25-dihydroxyvitamin D was within normal
limits (69 pmol/L, RR 38–183). Following the diagnosis of FS,
FAEs were stopped. There was partial improvement of the
symptoms with normalization of serum phosphate levels and
proteinuria.
Cases reported in Dutch and German national
pharmacovigilance databases
One case of FS linked to FAEs was reported to Lareb. This case
involved a 31-year-old female psoriasis patient. Her medical
history was remarkable for endometriosis, and she used celecox-
ib and a lynestrenol contraceptive. She had been treated with
FAEs for 5 years (dosage not reported). She developed FS with se-
vere osteomalacia. She had no symptoms except for a spontan-
eous bone fracture. FAE treatment was discontinued and the
patientwas treatedwith supplementation of phosphate and vita-
min D. The patient did not recover and became wheelchair
dependent.
Two cases of FS were reported by BfArM. A female patient
between 45 and 49 years of age was reported with FS. She had
been treated since 1989 with Fumaderm (dosage not reported)
and topical fumaric acid. In 1999, she developed FS, from which
she did not recover. She also developed osteomalacia, which
led to a pathologic fracture. The second case involved a female
psoriasis patient between 29 and 35 years of age who had been
treated with Fumaderm (dosage not reported) since 1995. She
was reportedwith FS (year of onset not reported) with a complete
recovery. She was diagnosed in 1998 with osteomalacia.
Discussion
FS is a renal disorder that is characterized by proximal tubular
dysfunction, which can lead to inappropriate urinary losses of
phosphate, glucose, bicarbonate and amino acids. Here, we re-
port 11 psoriasis patients who developed an FAE-induced FS. Pre-
senting symptoms of FS included generalized weakness and
myalgia. Laboratory tests typically showed low serum levels of
phosphate and uric acid and a proximal tubular acidosis, while
urinalysis showed glycosuria and proteinuria. Eight (73%) pa-
tients had hypophosphataemic osteomalacia and ﬁve (45%) pa-
tients had persisting symptoms despite FAE discontinuation.
The reported cases of FAE-associated FS share several pheno-
typical similarities. All cases involved females. Sex differences in
renal proximal tubular function and in the expression of organic
anion receptors have been described and such differences could
underlie differential risks for male and female patients to de-
velop FAE-associated FS [18, 19]. However, we cannot exclude se-
lective reporting due to the relatively small sample size described
in our case series. Whether there is a predominance for females
to develop FS remains to be determined. Furthermore, all pa-
tients reported with FS were treated long term with FAEs. The
median duration of FAEs treatment was 60 months (IQR 28–
111). The ﬁve cases that were published in the 1990s were linked
to the use of unlicensed FAEs formulations with dimethylfuma-
rate and monoethylfumarate salts. Moreover, the doses of FAEs
applied in these cases exceeded the maximum daily dose of
1290 mg that is recommended in current psoriasis guidelines
[4]. However, several of the patients were treated with lower do-
sages of FAEs and still developed FS (see Table 2). Therefore, a
clear correlation between FAE dosage and proximal tubular dys-
function cannot be made. Higher doses of FAEs per body weight
has been proposed as a potential factor in the nephrotoxicity of
FAEs [9]. The body mass index (BMI) was reported for only four
cases, with a median BMI for these cases of 20.9 kg/m2 (IQR
20.3–23.6). More data are needed to identify risk factors for the de-
velopment of FS during FAEs treatment.
Limitations of our study are the relatively small sample size
and the fact that causality between FAEs and drug-induced FS
cannot be proven in this data set. In addition, the data available
for some cases were incomplete for ﬁndings of proximal tubular
dysfunction. Also, some cases had limited data on alternative
causes of FS or use of prior and concomitant drugs that are
known to result in drug-induced FS. Two recent epidemiological
studies have shown an independent association betweenmoder-
ate-to-severe psoriasis and an increased risk for glomeruloneph-
ritis or chronic kidney disease [20, 21]. Psoriasis itself does not
seem to be associated with FS.
The incidence of FAE-associated FS has not been studied. In
randomized controlled trials that evaluated FAEs treatment in
psoriasis patients, no renal toxicity was reported [4]. This could
be due to the relatively short follow-up period in these trials.
Long-term observational studies have not indicated an increased
risk for nephrotoxicity during continuous FAE treatment [22, 23].
FS could be underdiagnosed, especially mild forms of proximal
tubular dysfunction, given that proteinuria is a recognized and
common adverse event of FAEs [24]. Up to 30% of patients display
proteinuria [25]. On the other hand, FAE-induced proteinuria is
typically transient, even with continued FAE treatment [4].
The current psoriasis guidelines recommend regular urinalysis
during FAEs, but there is no consensus on the optimal frequency.
The 2009 European S3 guidelines on psoriasis treatment recom-
mend monitoring serum creatinine and urine sediment every
4 weeks [4]. In the 2011 German psoriasis guidelines, it is ad-
vised to monitor serum creatinine and urine status every 4
weeks for the ﬁrst 4 months of treatment, followed by once
every 8 weeks [26]. Urinalysis is typically performed with a
urine dipstick, but this method is sensitive for albumin and
probably not reliable for detection of tubular proteinuria [27].
Tubular dysfunction leads to increased urinary levels of pro-
teins other than albumin, such as β2-microglobulin. Haring
et al. [9] assessed the use of β2-microglobulin in urine as amark-
er for proximal tubular damage during FAEs treatment in psor-
iasis patients. Urinary β2-microglobulin was increased in 3 of 23
patients receiving FAEs, which normalized upon discontinu-
ation of the FAEs. β2-microglobulin does not seem to be a sensi-
tive marker, which may be due to the collection method. β2-
microglobulin is not stable in acid urine and is only measurable
after alkalinization of the urine. A newmethod is measurement
of the urinary albumin:total protein ratio, which is an inexpen-
sive and simple screening test. If albumin constitutes <40% of
the total protein in urine, this is a good indication for tubular
proteinuria [28]. In our data set, we had no data available on
the urinary albumin:total protein ratio. Use of the urinary
albumin:total protein ratio as a screening test for tubular pro-
teinuria needs to be tested and validated for FAEs-induced FS.
FAEs are increasingly being used, also for conditions other
than psoriasis [29]. An FAE formulation containing dimethylfu-
marate (Tecﬁdera®, Biogen Idec) was approved for the treatment
of multiple sclerosis in 2013. Although the FAEs formulation and
the dosage schedule are different than those used in the treat-
ment of psoriasis, the safety proﬁle of this FAE formulation
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seemssimilar to thatof FAE treatment inpsoriasis. Therehavebeen
no reports of proximal tubular dysfunction with dimethylfumarate
in multiple sclerosis patients [30, 31].
The mechanisms leading to FAE-induced proximal tubular
dysfunction in FS are not understood [7]. One potential mechan-
ism involves FAE-induced glutathione depletion. FAEs are able to
enter proximal tubular cells via the organic anion transporter
(OAT1) [32] and deplete intracellular levels of glutathione levels
[33], which can cause FS [9, 34]. Maleic acid, a cis isomer of fumaric
acid, induces FS in rats through similar mechanisms of intracellu-
lar depletion of glutathione and adenosine triphosphate [35].
In conclusion, FS seems to be an infrequent adverse event of
FAE treatment. Female patients treated long term with FAEs
seem to be particularly at risk. Physicians treating patients with
FAEs should be aware of and vigilant for proximal tubular dys-
function during FAEs treatment. Quantitative total proteinmeas-
urement to calculate the albumin:total protein ratio is suggested
as a screening test for tubular proteinuria.
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